

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Quinn Tang *et al.*
Application No. : 10/588,602 Confirmation No. : 7130
Filed : June 13, 2007
For : RNAi THERAPEUTICS FOR TREATMENT OF EYE
NEOVASCULARIZATION DISEASES
Group Art Unit : 1635
Examiner : Dana H. Shin

New York, New York
May 19, 2010

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

STATEMENT OF SUBSTANCE OF INTERVIEW

Sir:

This responds to an April 20, 2010 Interview Summary in the above-identified application. Applicants submit herewith the required statement of the substance of the April 19, 2010 telephonic interview. Applicants are filing this statement before the expiration of the one-month or 30-day period from the mailing date of the Interview Summary. Thus, this statement is timely filed.

Applicants thank Examiner Shin for granting applicants' representative Alla Brukman the April 19, 2010 telephonic interview, and for her helpful comments during the interview. The Examiner and Ms. Brukman discussed the October 20, 2009 requirement for restriction. Ms. Brukman indicated that applicants wished to add new claims drawn to an inhibitor of a gene

that was not among the specific genes recited in the claims pending at issue date of the restriction requirement and to elect these claims for examination. The Examiner suggested that the new claims should depend from at least one of claims 1-5, which were included in all composition invention groups listed in the restriction requirement. Ms. Brukman inquired whether applicants could amend the base claim(s) selected from claims 1-5 to conform with the new claims, and the Examiner indicated that applicants could do so.

Respectfully submitted,

/Alla Brukman/

Jane T. Gunnison (Reg. No. 38,479)
Attorney for Applicants
Alla Brukman (Reg. No. 61,254)
Agent for Applicants

c/o ROPES & GRAY LLP
Customer No. 01473
1211 Avenue of the Americas
New York, New York 10036
Tel.: (212) 596-9000
Fax: (617) 235-9492